Top

Published in:

01-06-2007

A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy

Authors: Kai Bickenbach, Rebecca Wilcox, Jula Veerapong, Hedy Lee Kindler, Mitchell C. Posner, Amy Noffsinger, Kevin King Roggin

Published in: Journal of Gastrointestinal Surgery | Issue 6/2007

Abstract

Gastrointestinal stromal tumors are neoplastic lesions that arise from the interstitial cells of Cajal and are associated with somatic mutations in the tyrosine kinase receptor, KIT. The only known curative therapy is complete surgical resection. Unfortunately, postsurgical recurrence rates exceed 50% and most tumors are resistant to standard chemotherapy and radiation. Imatinib mesylate, a novel tyrosine kinase inhibitor, holds promise as a potential adjuvant therapy to prevent recurrence and improve long-term survival. However, as resistance data emerge, it appears that a potential “escape pathway” may originate from secondary mutations in the KIT receptor. This paper reviews the historical clinical experience with imatinib mesylate and discusses resistance patterns following targeted therapy. We highlight this review with an interesting case report that illustrates unique phenotypic tumoral changes associated with imatinib mesylate resistance.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51–58.PubMedCrossRef

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152(5):1259–1269.PubMed

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinem M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33(5):459–465.PubMedCrossRef

Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7(6):507–519.PubMedCrossRef

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577–580.PubMedCrossRef

Crosby JA, Catton CN, Davis A, Couture J, O’Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8(1):50–59.PubMedCrossRef

Rudolph P, Chiaravalli AM, Pauser U, Oschilies I, Hillemanns M, Gobbo M, Mariachal M, Eusebi V, Holfer H, Capella C, Kloppel G. Gastrointestinal mesenchymal tumors—immunophenotypic classification and survival analysis. Virchows Arch 2002;441(3):238–248.PubMedCrossRef

Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995;2(1):26–31.PubMedCrossRef

Patel S, Legha S, Salem P, Plager C, Papadoupolos N, Benjamin R. Evaluation of ifosfamide in metastatic leiomyosarcomas of GI origin. Proc Annu Meet Am Soc Clin Oncol 1991;31(352):Abstract 1252.

10.

Plager C, Papadoupolos N, Salem P, Benjamin R. Adriamycin-based chemotherapy for leiomyosarcoma of the stomach and small intestine. Proc Annu Meet Am Soc Clin Oncol 1991;10(352) Abstract 1251.

11.

Torihashi S, Nishi K, Tokutomi Y, Nishi T, Ward S, Sanders KM. Blockade of kit signaling induces transdifferentiation of interstitial cells of Cajal to a smooth muscle phenotype. Gastroenterology 1999;117(1):140–148.PubMedCrossRef

12.

Kluppel M, Huizinga JD, Malysz J, Bernstein A. Developmental origin and Kit-dependent development of the interstitial cells of Cajal in the mammalian small intestine. Dev Dyn 1998;211(1):60–71.PubMedCrossRef

13.

Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995;373(6512):347–349.PubMedCrossRef

14.

Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS. Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63(1):167–174.PubMedCrossRef

15.

Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999;31(10):1053–1074.PubMedCrossRef

16.

Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000;14(3):517–535.PubMedCrossRef

17.

Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61(22):8118–8121.PubMed

18.

Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11(8):728–734.PubMed

19.

Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999;18(10):1897–1902.PubMedCrossRef

20.

Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besmer P. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9(9):3329–3337.PubMed

21.

Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156(3):791–795.PubMed

22.

Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R, Michal M, Boltze C, Roessner A, Stachura J, Miettinen M. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003;34(12):1306–1312.PubMedCrossRef

23.

Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157(4):1091–1095.PubMed

24.

Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160(5):1567–1572.PubMed

25.

Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T, Kinoshita K, Chen H, Shinomura Y, Kitamura Y. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122(5):1493–1499.PubMedCrossRef

26.

Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y, Katsuyama T. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001;120(1):210–215.PubMed

27.

Hirota S, Okazaki T, Kitamura Y, O’Brien P, Kapusta L, Dardick I. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000;24(2):326–327.PubMedCrossRef

28.

Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157(5):1581–1585.PubMed

29.

Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29(1):52–68.PubMedCrossRef

30.

Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20(18):3898–3905.PubMedCrossRef

31.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561–566.PubMedCrossRef

32.

Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295(1):139–145.PubMed

33.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–1037.PubMedCrossRef

34.

Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90(12):4947–4952.PubMed

35.

Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001;33(7):451–455.PubMed

36.

Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 1962;8:65–66.PubMedCrossRef

37.

Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013–1035.PubMed

38.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344(14):1052–1056.PubMedCrossRef

39.

van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358(9291):1421–1423.PubMedCrossRef

40.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–216.PubMedCrossRef

41.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472–480.PubMedCrossRef

42.

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127–1134.PubMedCrossRef

43.

Rankin C, von Mehren M, Blanke CD, Benjamin R, Fletcher CD, Bramwell V, Crowley J, Borden E, Demetri G. Dose effect of imatinib in patients with metastatic GIST—Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004;22:819 (Abstract 9005).

44.

Judson I, Donato di Paola E, Verweij J, Van Glabbeke M, Ma P, Peng B, Dimitrijevic S, Van Oosterom A. Population pharmacokinetic analysis and pk-pharmacodynamic correlations in phase I/II trial of imatinib in gastrointestinal stromal tumors conducted by the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 2003;22:818.

45.

Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet 2005;162(1):57–62.PubMedCrossRef

46.

Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101(6):2152–2155.PubMedCrossRef

47.

Theou N, Gil S, Devocelle A, Julie C, Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A, Lemoine A, Faivre-Bonhomme L, Emile JF. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res 2005;11(21):7593–7598.PubMedCrossRef

48.

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40(5):689–695.PubMedCrossRef

49.

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11(11):4182–4190.PubMedCrossRef

50.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64(17):5913–5919.PubMedCrossRef

51.

Fletcher JA, Corless C, Dimitrijevic S, Von Mehren M, Eisenberg B, Joensuu H, Fletcher CD, Blanke CD, Demetri G, Heinrich MC. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumor. Proc Am Soc Clin Oncol 2003;22(3275):815.

52.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher J. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708–710.PubMedCrossRef

53.

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005;47(1):41–47.PubMedCrossRef

54.

Carney JA, Sheps SG, Go VL, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296(26):1517–1518.PubMedCrossRef

55.

Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999;74(6):543–552.PubMedCrossRef

56.

Diment J, Tamborini E, Casali P, Gronchi A, Carney JA, Colecchia M. Carney triad: case report and molecular analysis of gastric tumor. Hum Pathol 2005;36(1):112–116.PubMedCrossRef

57.

Spatz A, Bressac-de-Paillerets B, Raymond E. Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney’s triad. J Clin Oncol 2004;22(10):2029–2031.PubMedCrossRef

Title: A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy
Authors: Kai Bickenbach
Rebecca Wilcox
Jula Veerapong
Hedy Lee Kindler
Mitchell C. Posner
Amy Noffsinger
Kevin King Roggin
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 6/2007
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-007-0150-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2007

Middle Pancreatectomy: Why I Rarely Do It

Surgical Treatment of Crohn’s Disease

Co-morbidity is a Strong Predictor of Early Death and Multi-organ System Failure among Patients with Acute Pancreatitis

Middle Segment Pancreatectomy: A Useful Tool in the Management of Pancreatic Neoplasms

Stomach-Preserving Distal Pancreatectomy with Combined Resection of the Celiac Artery: Radical Procedure for Locally Advanced Cancer of the Pancreatic Body

Assessment of Pancreatic Neoplasms: Review of Biopsy Techniques